TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) insider Tamer I. Khayal sold 3,142 shares of the company’s stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $65.07, for a total transaction of $204,449.94. Following the sale, the insider now directly owns 1,300 shares of the company’s stock, valued at approximately $84,591. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
TransMedics Group Price Performance
TMDX stock traded down $0.46 during trading on Wednesday, reaching $66.97. 250,699 shares of the company were exchanged, compared to its average volume of 333,119. The company has a 50-day moving average of $59.59 and a two-hundred day moving average of $50.37. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of -44.91 and a beta of 1.58. TransMedics Group, Inc. has a twelve month low of $10.00 and a twelve month high of $68.43. The company has a debt-to-equity ratio of 0.31, a current ratio of 12.11 and a quick ratio of 11.21.
TransMedics Group (NASDAQ:TMDX – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.15. TransMedics Group had a negative net margin of 58.78% and a negative return on equity of 46.03%. The business had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $18.96 million. As a group, equities analysts predict that TransMedics Group, Inc. will post -1.3 earnings per share for the current fiscal year.
Hedge Funds Weigh In On TransMedics Group
Analyst Upgrades and Downgrades
TMDX has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on shares of TransMedics Group from $54.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, January 6th. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, November 4th. Finally, Cowen upped their price objective on shares of TransMedics Group from $60.00 to $70.00 in a research report on Friday, December 16th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $53.29.
TransMedics Group Company Profile
TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.